The Italian validation of the montreal global definition and classification of gastroesophageal reflux disease

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 4, 2009, Pages 304-318

  Pace, Fabio ^a   Bazzoli, Franco ^b   Fiocca, Roberto ^d   Mario, Francesco Di ^c   Savarino, Vincenzo ^d   Vigneri, Sergio ^e   Vakil, Nimish ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Barrett s esophagus; Extraesophageal symptoms; Gastroesophageal reflux disease; Gastroesophageal reflux disease definition

Indexed keywords

ANTACID AGENT; BENZODIAZEPINE; CAFFEINE; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ESOPHAGUS INJURY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL CARCINOMA; HEALTH PRACTITIONER; HEARTBURN; HUMAN; PRIORITY JOURNAL; SCORING SYSTEM; THORAX PAIN; VALIDATION STUDY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CHEST PAIN; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL STENOSIS; EVIDENCE-BASED MEDICINE; GASTROESOPHAGEAL REFLUX; HUMANS; ITALY; LANGUAGE; PRACTICE GUIDELINES AS TOPIC; SYNDROME; TERMINOLOGY AS TOPIC;

EID: 67649618870     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32830a70e2     Document Type: Article

References (133)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900-1920.
2. Ayres CG, Griffith HM. Perceived barriers to and facilitators of the implementation of priority clinical preventive services guidelines. Am J Manag Care 2007; 13:150-155.
3. Maue SK, Segal R, Kimberlin CL, Lipowski EE. Predicting physician guideline compliance: an assessment of motivators and perceived barriers. Am J Manag Care 2004; 10:383-391.
4. Heidrich J, Behrens T, Raspe F, Keil U. Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany. Eur J Cardiovasc Prev Rehabil 2005; 12:521-529.
5. Rastogi D, Shetty A, Neugebauer R, Harijith A. National Heart, Lung, and Blood Institute guidelines and asthma management practices among inner-city pediatric primary care providers. Chest 2006; 129:619-623.
6. Crim C. Clinical practice guidelines vs. actual clinical practice: the asthma paradigm. Chest 2000; 118 (2 Suppl):62S-64S.
7. Silagy CA, Weller DP, Lapsley H, Middleton P, Shelby-James T, Fazekas B. The effectiveness of local adaptation of nationally produced clinical practice guidelines. Fam Pract 2002; 19:223-230.
8. Petrie JC, Grimshaw JM, Bryson A. The Scottish Intercollegiate Guidelines Network Initiative: SIGN-getting validated guidelines into local practice. Health Bull (Edin) 1995; 53:345-348.
9. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton JL. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112:1448-1456.
10. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54:710-717.
11. Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adiis S, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96:52-57.
12. Stanghellini V, Armstrong D, Mönnikes H, Bardhan KD. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? Aliment Pharmacol Ther 2004; 19:463-479.
13. Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335:205-208.
14. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37:457-464.
15. Valle C, Broglia F, Pistorio A, Tinelli C, Perego M. Prevalence and impact of symptoms suggestive of gastroesophageal reflux disease. Dig Dis Sci 1999; 44:1848-1852.
16. Joelsson B, Johnsson F. Heartburn-the acid test. Gut 1989; 30:1523-1525.
17. Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut 2005; 54:1810-1817.
18. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux a meta-analysis. Gastroenterology 1997; 112:1798-1810.
19. Luostarinen M, Virtanen J, Koskinen M, Matikainen M, Isolauri J. Dysphagia and oesophageal clearance after laparoscopic versus open Nissen fundoplication. A randomized, prospective trial. Scand J Gastroenterol 2001; 36:565-571.
20. Lundell L, Miettinen P, Myrvold HE, Hatlebakk JG, Wallin L, Malm A, et al. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 2000; 12:879-887.
21. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease--current concepts and dilemmas. Am J Gastroenterol 2001; 96:303-314.
22. Trimble KC, Douglas S, Pryde A, Heading RC. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995; 40:1098-1104.
23. Meyer JH, Lembo A, Elashoff JD, Fass R, Mayer EA. Duodenal fat intensifies the perception of heartburn. Gut 2001; 49:624-628.
24. Fass R, Naliboff B, Higa L, Johnson C, Kodner A, Munakata J, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998; 115:1363-1373.
25. Pehlivanov N, Liu J, Mittal RK. Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 2001; 281:G743-G751.
26. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut 2002; 51:885-892.
27. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut 1999; 44 (Suppl 2):S1-S16.
28. Baldi F, Ferrarini F, Longanesi A, Ragazzini M, Barbara L. Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association. Dig Dis Sci 1989; 34:1890-1893.
29. Pilotto A, Di Mario F, Malfertheiner P, Valerio G, Naccarato R. Upper gastrointestinal diseases in the elderly: report of a meeting held at Vicenza, Italy, on 20 March 1998. Eur J Gastroenterol Hepatol 1999; 11:801-808.
30. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17:537-545.
31. Frazzoni M, Manno M, De Micheli E, Savarino V. Pathophysiological characteristics of the various forms of gastro-oesophageal reflux disease. Spectrum disease or distinct phenotypic presentations? Dig Liver Dis 2006; 38:643-648.
32. Dean BB, Gano AD Jr, Knight K, Offman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2:656-664.
33. Galmiche JP, Clouse RE, Bálint A, Cook JI, Kahrilas PJ, Paterson WG, et al. Functional esophageal disorders. Gastroenterology 2006; 130:1459-1465.
34. Watson RG, Tham TC, Johnston BT, McDougall MJ. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux-the ‘sensitive oesophagus’. Gut 1997; 40:587-590.
35. Zentilin P, Della Casa D, Fanucchi M, Savarino V. 24-h ambulatory intraluminal pH-impedance in patients with non erosive reflux disease (NERD). Gastroenterology 2007; 132 (Suppl 2):A140.
36. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120:1599-1606.
37. Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006; 93:1483-1487.
38. Savarino V, Savarino E, Dulbecco P. Proton pump inhibitor failure: why does it occur and how can it be managed? Digestion 2006; 73:215-217.
39. Vakil N. Epigastric pain in dyspepsia and reflux disease. Rev Gastroenterol Disord 2003; 3 (Suppl 4):S16-S21.
40. Strignano P, Collard JM, Michel JM, Romagnoli R, Buts JP, De Gheldere C, et al. Duodenal switch operation for pathologic transpyloric duodenogastric reflux. Ann Surg 2007; 245:247-253.
41. Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N; ROSE Trial Investigators. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol 2006; 41:1132-1140.
42. Tack J, Caenepeel P, Arts J, Lee KJ, Sifrim F, Janssens J. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 2005; 54:1370-1376.
43. Orr WC, Craddock A, Goodrich S. Acidic and non-acidic reflux during sleep under conditions of powerful acid suppression. Chest 2007; 131:460-465.
44. Orr WC. Esophageal function during sleep: another danger in the night. Sleep Med 2007; 8:105-106; Epub 2007 Feb 1. No abstract available.
45. Bruley des Varannes S, Errieau G, Tessier C. Two thirds of patients with gastroesophageal reflux have nocturnal symptoms: survey by 562 general practitioners of 36663 patients. Press Med 2007; 36 (4 Pt 1):591-597. Epub 2007 Jan 30. French.
46. Dubois RW, Aguilar D, Fass R, Orr WC, Elfant AB, Dean BB, et al. Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity. Aliment Pharmacol Ther 2007; 25:487-500.
47. Kasasbeh A, Kasasbeh E, Krishnaswamy G. Potential mechanisms connecting asthma, esophageal reflux, and obesity/sleep apnea complex - a hypothetical review. Sleep Med Rev 2007; 11:47-58; Epub 2007 Jan 2. Review.
48. Tawk M, Goodrich S, Kinasewitz G, Orr W. The effect of 1 week of continuous positive airway pressure treatment in obstructive sleep apnea patients with concomitant gastroesophageal reflux. Chest 2006; 130:1003-1008.
49. Fass R, Quan SF, O’Connor GT, Ervin A, Iber C. Predictors of heartburn during sleep in a large prospective cohort study. Chest 2005; 127:1658-1666.
50. Dernaika T, Tawk M, Nazir S, Younis W, Kinasewitz GT. The significance and outcome of continuous positive airway pressure-related central sleep apnea during split-night sleep studies. Chest 2007; 132:81-87.
51. Graf KI, Karaus M, Heinemann S, Koerber S, Dorow P, Hampel S. Gastroesophageal reflux in patients with sleep apnea syndrome. Z Gastroenterol 1995; 33:689-693.
52. Sontag SJ. Defining GERD. Yale J Biol Med 1999; 72:69-80.
53. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003; 98:1487-1493.
54. Draaisma WA, Ruurda JP, Scheffer RC, Simmermacher RK, Gooszen HG, Rijnhart-de Jong HG, et al. Randomized clinical trial of standard laparoscopic versus robot-assisted laparoscopic Nissen fundoplication for gastro-oesophageal reflux disease. Br J Surg 2006; 93:1351-1359.
55. Mehta S, Bennett J, Mahon D, Rhodes M. Prospective trial of laparoscopic nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: Seven-year follow-up. J Gastrointest Surg 2006; 10:1312-1316; discussion 1316-7.
56. Van Nieuwenhoven MA, Brouns F, Brummer RJ. Gastrointestinal profile of symptomatic athletes at rest and during physical exercise. Eur J Appl Physiol 2004; 91:429-434. Epub 2003 Nov 22.
57. Jozkow P, Wasko-Czopnik D, Medras M, Paradowski L. Gastroesophageal reflux disease and physical activity. Sports Med 2006; 36:385-391.
58. Bennett J. ABC of the upper gastrointestinal tract. Oesophagus: atypical chest pain and motility disorders. Br Med J 2001; 323:791-794.
59. Eslick GD. Usefulness of chest pain character and location as diagnostic indicators of an acute coronary syndrome. Am J Cardiol 2005; 95:1228-1231.
60. Mousavi S, Tosi J, Eskandarian R, Zahmatkesh M. Role of clinical presentation in diagnosing reflux-related non-cardiac chest pain. J Gastroenterol Hepatol 2007; 22:218-221.
61. Chiocca JC, Olmos JA, Salis GB, Soifer LO, Higa R, Marcolongo M, et al. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: a nationwide population-based study. Aliment Pharmacol Ther 2005; 22:331-342.
62. Kim JH, Rhee PL, Park EH, Lee H, Choi YS, Son HJ, et al. Clinical usefulness of subgrouping of patients with non-cardiac chest pain according to characteristic symptoms in Korea. J Gastroenterol Hepatol 2007; 22:320-325.
63. Fass R. Sensory testing of the esophagus. J Clin Gastroenterol 2004; 38:628-641.
64. Dickman R, Mattek N, Holub J, Peters D, Fass R. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database. Am J Gastroenterol 2007; 102:1173-1179.
65. Cherian P, Smith LF, Bardhan KD, Smallwood RH. Esophageal tests in the evaluation of non-cardiac chest pain. Dis Esophagus 1995; 8:129-133.
66. Dekel R, Pearson T, Wendel C, De Garmo P, Fennerty MB, Fass R. Assessment of oesophageal motor function in patients with dysphagia or chest pain-the Clinical Outcomes Research Initiative experience. Aliment Pharmacol Ther 2003; 8:1083-1089.
67. Katz PO, Dalton CB, Richter JE, Wu WC, Castell DO. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years’ experience with 1161 patients. Ann Intern Med 1987; 106:593-597.
68. Dickman R, Fass R. Noncardiac chest pain. Clin Gastroenterol Hepatol 2006; 4:558-563.
69. Fass R, Dickman R. Non-cardiac chest pain: an update. Neurogastroenterol Motil 2006; 18:408-417.
70. Cremonini F, Wise J, Moayyedi P, Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005; 100:1226-1232.
71. Wang WH, Huang JQ, Zheng GF, Wong WM, Lam SK, Karlberg J, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain?: a meta-analysis. Arch Intern Med 2005; 165:1222-1228.
72. Malfertheiner P, Hallerbäck B. Clinical manifestations and complications of gastroesophageal reflux disease (GERD). Int J Clin Pract 2005; 59:346-355.
73. Ruigómez A, García Rodríguez LA, Wallander MA, Johansson S, Eklund S. Esophageal stricture: incidence, treatment patterns, and recurrence rate. Am J Gastroenterol 2006; 101:2685-2692.
74. El-Serag HB. Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol 2006; 101:1727-1733.
75. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007; 5:4-16.
76. Tobey NA, Carson JL, Alkiek RA, Orlando RC. Dilated intercellular spaces: a morphological feature of acid reflux-damaged human esophageal epithelium. Gastroenterology 1996; 111:1200-1205.
77. Calabrese C, Bortolotti M, Fabbri A, Cenacchi G, Carlo S, Zalhane D, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005; 100:537-542.
78. Caviglia R, Ribolsi M, Maggiano N, Gabbrielli M, Emerenziani S, Guarino MP, et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am J Gastroenterol 2005; 100:543-548.
79. Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dulbecco P, Pigozzi S, et al. Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group. Am J Gastroenterol 2005; 100:2299-2306.
80. Kahrilas PJ. Dilated intercellular spaces: extending the reach of the endoscope. Am J Gastroenterol 2005; 100:549-550.
81. Pace F, Bollani S, Molteni P, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) - a reappraisal 10 years on. Dig Liver Dis 2004; 36:111-115.
82. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyriläinen O, et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92:37-41.
83. McDougall NI, Johnston BT, Collins JS, McFarland RJ, Love AH. Three- to 4.5-year prospective study of prognostic indicators in gastro-oesophageal reflux disease. Scand J Gastroenterol 1998; 33:1016-1022.
84. Kuster E, Ros E, Toledo-Pimentel V, Pujol A, Bordas JM, Grande L, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut 1994; 35:8-14.
85. Bajbouj M, Reichenberger J, Neu B, Prinz C, Schmid RM, Roesch T, et al. A prospective multicenter clinical and endoscopic follow-up study of patients with gastroesophageal reflux disease. Z Gastroenterol 2005; 43:1303-1307.
86. Labenz J, Nocon M, Lind T, Leodolter A, Jaspersen D, Meyer-Sabellek D, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006; 101:2457-2462.
87. Fullard M, Kang JY, Neild P, Poullis A, Maxwell JD. Systematic review: does gastro-oesophageal reflux disease progress? Aliment Pharmacol Ther 2006; 24:33-45.
88. Saraswat VA, Dhiman RK, Mishra A, Naik SR. Correlation of 24-h esophageal pH patterns with clinical features and endoscopy in gastroesophageal reflux disease. Dig Dis Sci 1994; 39:199-205.
89. Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2004; 2:665-668.
90. Kapoor N, Bassi A, Sturgess R, Bodger K. Predictive value of alarm features in a rapid access upper gastrointestinal cancer service. Gut 2005; 54:40-45.
91. Fransen GA, Janssen MJ, Muris JW, Lahejj RJ, Jansen GB. Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy. Aliment Pharmacol Ther 2004; 20:1045-1052.
92. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology 1996; 110:614-621.
93. Sampliner RE. Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol 2002; 97:1888-1895.
94. Meining A, Ott R, Becker I, Hahn S, Muehlen J, Werner M, et al. The Munich Barrett follow up study: suspicion of Barrett’s oesophagus based on either endoscopy or histology only--what is the clinical significance? Gut 2004; 53:1402-1407.
95. Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc 2003; 58:661-670.
96. Lieberman DA, Oehlke M, Helfand M. Risk factors for Barrett’s esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997; 92:1293-1297.
97. Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett’s esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol 2001; 96:2005-2012.
98. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111:1192-1199.
99. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett’s esophagus in asymptomatic individuals. Gastroenterology 2002; 123:461-467.
100. British Society of Gastroenterology: guidelines for the diagnosis and management of Barrett’s columnar-lined oesophagus. 2005, http://www.bsg.org.uk
101. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, et al. Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett’s esophagus without grossly recognizable neoplastic lesions. Gastroenterology 1988; 94:81-90.
102. Reid BJ, Blount PL, Feng Z, Levine DS. Optimizing endoscopic biopsy detection of early cancers in Barrett’s high-grade dysplasia. Am J Gastroenterol 2000; 95:3089-3096.
103. Wang KK, Wongkeesong M, Buttar NS. American Gastroenterological Association technical review on the role of the gastroenterologist in the management of esophageal carcinoma. Gastroenterology 2005; 128:1471-1505.
104. Sharma P, Weston AP, Topalovski M, Cherian R, Bhattacharyya A, Sampliner RE. Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett’s oesophagus. Gut 2003; 52:24-27.
105. Hamamoto Y, Endo T, Nosho K, Arimura J, Sato M, Imai K. Usefulness of narrow-band imaging endoscopy for diagnosis of Barrett’s esophagus. J Gastroenterol 2004; 39:14-20.
106. Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 2002; 97:1930-1936.
107. Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000; 132:612-620.
108. Csendes A, Smok G, Burdiles P, Kom O, Gradiz M, Rojas J, et al. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. Dis Esophagus 2003; 16:24-28.
109. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett’s multifocal high-grade dysplasia or adenocarcinoma. Am J Gastroenterol 1999; 94:3413-3419.
110. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C & M criteria. Gastroenterology 2006; 131:1392-1399.
111. Santana J, Khan M, Vakil N, Lundell L. Systematic review of adenocarcinoma risk in Barrett’s esophagus with particular reference to short segment Barrett’s esophagus and intestinal metaplasia. Gastroenterology 2006; 130 (Suppl 2):A264.
112. Shaheen NJ, Dulai GS, Ascher B, Mitchell KL, Schmitz SM. Effect of a new diagnosis of Barrett’s esophagus on insurance status. Am J Gastroenterol 2005; 100:577-580.
113. Lagergren J, Bergström R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340:825-831.
114. Cameron AJ, Lomboy CT, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett’s esophagus. Gastroenterology 1995; 109:1541-1546.
115. Clark GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M. Is Barrett’s metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994; 129:609-614.
116. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux. Gut 2004; 53:1070-1074.
117. El-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 1997; 113:755-760.
118. Gislason T, Janson C, Vermeire P, Plaschke P, Björnsson E, Gislason D, et al. Respiratory symptoms and nocturnal gastroesophageal reflux: a population-based study of young adults in three European countries. Chest 2002; 121:158-163.
119. Irwin RS, French CL, Curley FJ, Zawacki JK, Bennett FM. Chronic cough due to gastroesophageal reflux. Clinical, diagnostic, and pathogenetic aspects. Chest 1993; 104:1511-1517.
120. Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. Br Med J 2006; 332:11-17.
121. Adhami T, Goldblum JR, Richter JE, Vaezi MF. The role of gastric and duodenal agents in laryngeal injury: an experimental canine model. Am J Gastroenterol 2004; 99:2098-2106.
122. Tuchman DN, Boyle JT, Pack AI, Scwartz J, Kokonos M, Spitzer AR, et al. Comparison of airway responses following tracheal or esophageal acidification in the cat. Gastroenterology 1984; 87:872-881.
123. Field SK, Evans JA, Price LM. The effects of acid perfusion of the esophagus on ventilation and respiratory sensation. Am J Respir Crit Care Med 1998; 157:1058-1062.
124. Ing AJ, Ngu MC, Breslin AB. Pathogenesis of chronic persistent cough associated with gastroesophageal reflux. Am J Respir Crit Care Med 1994; 149:160-167.
125. Kiljander TO, Harding SM, Field SK, Stein MK, Nelson HS, Ekelund J, et al. Effects of esomeprazole 40mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173:1091-1097.
126. Vaezi MF, Richter JE, Stasney CR, Spiegel GR, Iannuzzi RA, Crawley JA, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006; 116:254-260.
127. Qadeer MA, Phillips CO, Lopez AR, Steward DL, Noordzij JP, Wo JM, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101:2646-2654.
128. Gatta L, Vaira D, Sorrenti G, Zucchini S, Sama C, Vakil N. Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007; 25:385-392.
129. Muñoz JV, Herreros B, Sanchiz V, Amoros C, Hernandez V, Pascual I, et al. Dental and periodontal lesions in patients with gastro-oesophageal reflux disease. Dig Liver Dis 2003; 35:461-467.
130. Böhmer CJ, Klinkenberg-Knol EC, Niezen-de Boer MC, Meuwissen SG. Dental erosions and gastro-oesophageal reflux disease in institutionalized intellectually disabled individuals. Oral Dis 1997; 3:272-275.
131. Schroeder PL, Filler SJ, Ramirez B, Lazarchik DA, Vaezi MF, Richter JE, et al. Dental erosion and acid reflux disease. Ann Intern Med 1995; 122:809-815.
132. Pace F, Pallotta S, Tonini M, Vakil N, Bianchi Porro G. Systematic review. Gastro-oesophageal reflux disease and dental erosion. Aliment Pharmacol Ther 2008; 27:1179-1186.
133. Bortolotti M, Gentilini L, Morselli C, Giovannini M. Obstructive sleep apnoea is improved by a prolonged treatment of gastrooesophageal reflux with omeprazole. Dig Liver Dis 2006; 38:78-81.